Ironwood Pharmaceuticals (IRWD) Income towards Parent Company: 2009-2024
Historic Income towards Parent Company for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to $102.8 million.
- Ironwood Pharmaceuticals' Income towards Parent Company rose 999.29% to $40.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $130.5 million, marking a year-over-year increase of 156.81%. This contributed to the annual value of $102.8 million for FY2024, which is 108.17% up from last year.
- Latest data reveals that Ironwood Pharmaceuticals reported Income towards Parent Company of $102.8 million as of FY2024, which was up 108.17% from -$1.3 billion recorded in FY2023.
- Over the past 5 years, Ironwood Pharmaceuticals' Income towards Parent Company peaked at $528.5 million during FY2021, and registered a low of -$1.3 billion during FY2023.
- In the last 3 years, Ironwood Pharmaceuticals' Income towards Parent Company had a median value of $102.8 million in 2024 and averaged -$326.8 million.
- In the last 5 years, Ironwood Pharmaceuticals' Income towards Parent Company soared by 397.79% in 2021 and then slumped by 818.82% in 2023.
- Yearly analysis of 5 years shows Ironwood Pharmaceuticals' Income towards Parent Company stood at $106.2 million in 2020, then spiked by 397.79% to $528.5 million in 2021, then tumbled by 66.88% to $175.0 million in 2022, then plummeted by 818.82% to -$1.3 billion in 2023, then soared by 108.17% to $102.8 million in 2024.